K2 Principal Fund, L.P. Pharma Cyte Biotech, Inc. Transaction History
K2 Principal Fund, L.P.
- $210 Million
- Q3 2024
A detailed history of K2 Principal Fund, L.P. transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, K2 Principal Fund, L.P. holds 209,266 shares of PMCB stock, worth $334,825. This represents 0.19% of its overall portfolio holdings.
Number of Shares
209,266
Previous 327,503
36.1%
Holding current value
$334,825
Previous $641,000
37.75%
% of portfolio
0.19%
Previous 0.33%
Shares
9 transactions
Others Institutions Holding PMCB
# of Institutions
30Shares Held
932KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA192KShares$307,8190.0% of portfolio
-
Geode Capital Management, LLC Boston, MA168KShares$269,1200.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$147,3397.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$132,3630.17% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.7KShares$79,5200.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $33.2M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...